The Biotech Rollercoaster Ride: From Lab To Buyout
Caixa Capital Risc's Pablo Cironi On Sanifit's Story
Executive Summary
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
You may also be interested in...
Spain Biotech Boost As Minoryx Raises €21m
Spain's biotech start-ups are building an impressive pipeline of drugs but have found financing a challenge, so news of fresh funds for rare diseases group Minoryx has been cheered by the sector.
Anger Over Access To AstraZeneca's Evusheld Peaks In UK
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.
Big Pharmas Trust To The Science In Zantac Lawsuits
Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link.